COVID-19 Investigational Treatments in Use Among Hospitalized Patients Identified Through the US Coronavirus Disease 2019–Associated Hospitalization Surveillance Network, March 1–June 30, 2020

Using a coronavirus disease 2019 (COVID-19)–associated hospitalization surveillance network, we found that 42.5% of hospitalized COVID-19 cases with available data from March 1–June 30, 2020, received ≥1 COVID-19 investigational treatment. Hydroxychloroquine, azithromycin, and remdesivir were used f...

Descripción completa

Detalles Bibliográficos
Autores principales: Acosta, Anna M, Mathis, Adria L, Budnitz, Daniel S, Geller, Andrew I, Chai, Shua J, Alden, Nisha B, Meek, James, Anderson, Evan J, Ryan, Patricia, Kim, Sue, Como-Sabetti, Kathryn, Torres, Salina, Dufort, Elizabeth, Bennett, Nancy M, Billing, Laurie M, Sutton, Melissa, Keipp Talbot, H, George, Andrea, Pham, Huong, Hall, Aron J, Fry, Alicia, Garg, Shikha, Kim, Lindsay
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7686662/
https://www.ncbi.nlm.nih.gov/pubmed/33274249
http://dx.doi.org/10.1093/ofid/ofaa528
Descripción
Sumario:Using a coronavirus disease 2019 (COVID-19)–associated hospitalization surveillance network, we found that 42.5% of hospitalized COVID-19 cases with available data from March 1–June 30, 2020, received ≥1 COVID-19 investigational treatment. Hydroxychloroquine, azithromycin, and remdesivir were used frequently; however, hydroxychloroquine and azithromycin use declined over time, while use of remdesivir increased.

Ejemplares similares